Product Description
Propoxyphene napsylate differs from the hydrochloride salt in several ways. It is much less soluble and bitter and poses few stability problems when capsulated or tableted with aspirin. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10824/)
Mechanisms of Action: OPRM Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: India | South Africa
Approved Indications: None
Known Adverse Events: None
Company: Xanodyne
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
XP20C-101 | P4 |
Terminated |
Healthy Volunteers |
2010-11-01 |